Skip to main content

Animations

MJFF Publications

2791 - 2800 of 6082 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • Summary Details
    OPEN
    Title: Distinct neural circuits are associated with subclinical neuropsychiatric symptoms in Parkinson's disease
    Journal Name: Journal of the Neurological Sciences
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.jns.2021.117365
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson disease and scans without evidence of dopaminergic deficit
    Journal Name: Medicine
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1097/md.0000000000024837
    Citation Count: 14
  • Summary Details
    OPEN
    Title: LRRK2 Ablation Attenuates Alpha-Synuclein–Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s13311-021-01007-8
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson’s disease cohort
    Journal Name: Human Molecular Genetics
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/hmg/ddab058
    Citation Count: 28
  • Summary Details
    OPEN
    Title: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30489-0
    Citation Count: 103
  • Summary Details
    OPEN
    Title: A 2-Pyridone Amide Inhibitor of Transcriptional Activity in Chlamydia trachomatis
    Journal Name: Antimicrobial Agents and Chemotherapy
    Publisher: American Society for Microbiology
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1128/aac.01826-20
    Citation Count: 5
  • Summary Details
    OPEN
    Title: PathoFact: a pipeline for the prediction of virulence factors and antimicrobial resistance genes in metagenomic data
    Journal Name: Microbiome
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40168-020-00993-9
    Citation Count: 132
  • Summary Details
    OPEN
    Title: Investigating ELOVL7 coding variants in multiple system atrophy
    Journal Name: Neuroscience Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: publisher-specific-oa
    DOI - Digital Object Identifier: 10.1016/j.neulet.2021.135723
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain
    Journal Name: Brain Research
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.brainres.2021.147372
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture
    Journal Name: Nature Genetics
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41588-021-00785-3
    Citation Count: 276
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.